GSK (GSK) vs Regeneron Pharmaceuticals (REGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Regeneron Pharmaceuticals (REGN) has outperformed GSK (GSK) over the past year, gaining 27.2% versus a gain of 8.1%. Over five years, REGN leads with a +34.1% price change compared with +20.5% for GSK. GSK is the larger company by market cap ($94.21 billion vs $76.40 billion), about 1.2 times the size.
On valuation, GSK trades at a lower forward P/E (9.5x vs 12.1x for Regeneron Pharmaceuticals). GSK offers the higher dividend yield (1.45% vs 0.49%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GSK | REGN |
|---|---|---|
| Share price | $47.02 | $742.12 |
| Market cap | $94.21B | $76.40B |
| 1-day change | +0.90% | +0.46% |
| YTD return | -4.12% | -3.85% |
| 1-year return | +8.09% | +27.24% |
| 5-year return | +20.53% | +34.14% |
| P/E ratio (TTM) | 14.83 | 18.35 |
| Forward P/E | 9.52 | 12.07 |
| EPS (TTM) | $3.17 | $40.44 |
| Dividend yield | 1.45% | 0.49% |
| Annual dividend | $0.68 | $3.64 |
| Revenue (latest FY) | — | $14.34B |
| Revenue growth (YoY) | — | +0.99% |
| Net income (latest FY) | — | $4.50B |
| Operating margin | — | 24.95% |
| Net margin | — | 31.41% |
| 52-week high | $61.70 | $859.34 |
| 52-week low | $42.85 | $541.00 |
| Distance from 52-week high | -23.79% | -13.64% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +26.18% | +15.38% |
| Average volume | 3.77M | 739.67K |
| Shares outstanding | 2.00B | 101.14M |
| Employees | 66,841 | 15,410 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REGN has outperformed GSK by 19.1 percentage points over the past year.
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
GSK vs REGN FAQ
Which is bigger, GSK or Regeneron Pharmaceuticals?
GSK (GSK) is larger, with a market capitalization of $94.21B compared with $76.40B for Regeneron Pharmaceuticals (REGN).
Which stock has performed better over the past year, GSK or REGN?
REGN returned +27.24% over the past 12 months, compared with +8.09% for GSK (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GSK or REGN?
GSK has the lower trailing P/E at 14.8, versus 18.4 for REGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, GSK or Regeneron Pharmaceuticals?
GSK has the higher yield at 1.45%, compared with 0.49% for Regeneron Pharmaceuticals.
Are GSK and Regeneron Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.